

Status Conference Hearing held on 4/15/2025. (RE: related document(s) [779] Motion for contempt against Eiger InnoTherapeutics, Inc. (n/k/a EIT Pharma, Inc.) regarding the Zokinvy Sale Order Sentynl Therapeutics, Inc.'s Motion (I) to Enforce the Zokinvy Sale Order and (II) For Contempt Against Eiger Innotherapeutics, Inc., filed by Interested Party Sentynl Therapeutics, Inc. (Appearances: H. Ray, III, J. Morris, J. Dickenson, R. Trechter, and M. Stromberg for Senynl; W. Martin, R. Parisi, and M. Venus for Liquidating Trustee; J. Brookner and E. Shanks for EIT; C. Carson for Progeria Foundation. Nonevidentiary status conference. After hearing statements of counsel, court determined this contested matter will be tried jointly with Request for Allowance of an Administrative Expense claim, DE # 729, all parties agreeing that no adversary proceeding is needed/requested. This matter will also be tried with EIT Motion at DE # 707. Joint Scheduling Order to be

